Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 2/20 | 0.47 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
| ▸ | MMP13 | P45452 | 3/20 | 0.36 |
| ▸ | ADAM17 | P78536 | 3/20 | 0.36 |
| ▸ | MMP2 | P08253 | 2/20 | 0.36 |
| ▸ | MMP14 | P50281 | 1/20 | 0.36 |
| ▸ | NAMPT | P43490 | 1/20 | 0.36 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.36 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29346988 | 0.93 | CYP4F2 (0.54) | CYP4F2CYP4A11PKMUSP2SMN1; SMN2 | |
| SCHEMBL1958618 | 0.88 | PKM (0.48) | CYP4F2CYP4A11PKMUSP2SMN1; SMN2 | |
| SCHEMBL21233488 | 0.87 | CYP4F2 (0.47) | CYP4F2CYP4A11PKMUSP2SMN1; SMN2 | |
| SCHEMBL17761472 | 0.86 | PKM (0.44) | CYP4F2CYP4A11PKMUSP2SMN1; SMN2 | |
| SCHEMBL21225828 | 0.85 | CYP4F2 (0.46) | CYP4F2CYP4A11PKMUSP2SMN1; SMN2 | |
| SCHEMBL4767476 | 0.85 | PKM (0.45) | CYP4F2CYP4A11PKMUSP2SMN1; SMN2 | |
| SCHEMBL4774435 | 0.85 | PKM (0.45) | CYP4F2CYP4A11PKMUSP2SMN1; SMN2 | |
| SCHEMBL21963889 | 0.84 | PKM (0.47) | CYP4F2CYP4A11PKMUSP2SMN1; SMN2 | |
| SCHEMBL4792775 | 0.84 | PKM (0.44) | CYP4F2CYP4A11PKMUSP2SMN1; SMN2 | |
| SCHEMBL20475488 | 0.83 | PKM (0.47) | CYP4F2CYP4A11PKMUSP2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11578072-B2 | Spiro-lactam NMDA receptor modulators and uses thereof | APTINYX INC. (US) | 2023-02-14 | — | — | US | disclosed |
| US-20210040095-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | TENACIA BIOTECHNOLOGY (HONG KONG) CO., LIMITED (HK) | 2021-02-11 | — | — | US | disclosed |
| CN-112204031-A | Spiro-lactam NMDA receptor modulators and uses thereof | 阿普廷伊克斯股份有限公司 | 2021-01-08 | — | — | CN | disclosed |
| WO-2019152687-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | APTINYX INC. (US) | 2019-08-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11578072-B2 | Spiro-lactam NMDA receptor modulators and uses thereof | GRIN1, GRIN2A, GRIN2B | CYP4F2 3164/4885CYP4A11 3170/4885PKM 1085/4885 |
| US-20210040095-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | GRIN1, GRIN2A, GRIN2B | CYP4F2 3164/4885CYP4A11 3170/4885PKM 1085/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.